Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH

Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH

Dysregulation of glucose homeostasis plays a major role in the pathogenesis of non-alcoholic steatohepatitis (NASH) as it activates proinflammatory and profibrotic processes. Beneficial effects of antiglycemic treatments such as GLP-1 agonist or SGLT-2 inhibitor on NASH in patients with diabetes hav...

Full description

Bibliographic Details
Main Authors: Katharina Luise Hupa-Breier, Janine Dywicki, Björn Hartleben, Freya Wellhöner, Benjamin Heidrich, Richard Taubert, Young-Seon Elisabeth Mederacke, Maren Lieber, Konstantinos Iordanidis, Michael P. Manns, Heiner Wedemeyer, Matthias Hardtke-Wolenski, Elmar Jaeckel
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Biomedicines
Subjects:
liver disease
non-alcoholic steatohepatitis
GLP-1 agonist
SGLT-2 inhibitor
type 2 diabetes
innate immune system
Online Access:https://www.mdpi.com/2227-9059/9/4/353

Similar Items

Similar Items